WARF: P05256US

Multilayer Tissue Regeneration System


William Murphy

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method for regenerating natural skeletal tissues that more closely mimics in vivo conditions than current methods.
OVERVIEWUnder physiological conditions, bone tissue regeneration involves a complex interplay of multiple biologically active molecules and stem cells. The molecules are often presented sequentially in cascades, where each factor has a distinct effect on the cells of a growing bone.
THE INVENTIONA UW-Madison researcher has developed an approach for regenerating natural skeletal tissues that more closely mimics in vivo conditions by localizing and temporally controlling the activity of multiple growth factors. This method for growing tissue is based on a matrix of minerals and growth factors. Engineered protein growth factors are incorporated into the layers of the inorganic matrix. Each layer is designed to dissolve at a separate rate. As the matrix material gradually breaks down, the growth factors are delivered sequentially, enabling the growth of new bone tissue. Alternatively, the growth factors can be engineered to bind to the surface of the inorganic matrix.
  • Regeneration of bone and other tissues
  • Treatment of musculoskeletal conditions
  • Research on organ and tissue development
  • May enable new treatment options for musculoskeletal injuries, diseases and conditions
  • Potentially could expand the range of orthopedic conditions that can be effectively treated
  • May be more economical than current metallic, hardware-based bone replacement methods
  • The matrix material breaks down at the same time new bone grows, allowing for improved delivery of growth factors to promote the new bone growth that will slowly replace the implant.
  • Provides a structural matrix for tissue ingrowth
  • Released growth factor is bioactive and in close proximity to the cell type(s) of interest
  • Because the implant is based on a mineral, rather than a polymer, it is a better match to the in vivo bone environment.
Contact Information
For current licensing status, please contact Jeanine Burmania at or 608-960-9846.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.